Navigation Links
Laureate Announces Second Manufacturing Agreement with Cytheris
Date:3/27/2008

Laureate to Manufacture Cytheris' Lead Product Candidate, INTERLEUKIN-7,

currently in clinical trials for treatment of HIV, HCV and cancer

PRINCETON, N.J. and PARIS, March 27 /PRNewswire-FirstCall/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, announced today that it has entered into a cGMP contract manufacturing agreement with Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation. According to the agreement, Laureate will manufacture Cytheris' lead product candidate, Interleukin-7 (IL-7), a fully glycosylated recombinant human protein and critical growth factor for immune T-cell recovery, for use in ongoing international clinical trials currently being conducted for treatment of HIV, HCV and cancer. Terms and conditions of the agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

Recombinant human Interleukin-7 (r-hIL-7) is a critical growth factor for immune T-cell recovery and enhancement. Clinical investigations conducted on more than 75 patients in Europe, the U.S. and Canada have suggested the potential of r-hIL-7 to expand and protect CD4+ and CD8+ T-cells.

"We are delighted that Cytheris has selected us again as their CMO, to manufacture IL-7 in support of their expanded clinical trial program. This is a testimonial to our successful partnership with our clients and our effort to achieve their total satisfaction in our ability to meet their manufacturing needs," said Robert J. Broeze, Ph.D., President & CEO of Laureate. "We will work with the Cytheris team very closely and help them realize the greatest potential of their IL-7 development and production program."

"As we move towards large scale production of our IL-7 biotherapeutic, we are pleased to continue our strong working relationship with Laureate Pharma," said Michel Morre, DVM, President and CEO of Cytheris. "With Laureate's demonstrated skill in successful transfer of process technology, we look forward to continuing to work together in the process scale-up, engineering and clinical material production of IL-7 for our ongoing clinical trials investigating multiple indications."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE) (http://www.safeguard.com). For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or info@laureatepharma.com or visit http://www.laureatepharma.com.

About Cytheris SA

Cytheris SA is a privately held clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune systems of patients suffering from cancer, chronic viral or bacterial infections such as HIV and HCV, or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT). The company operates from its headquarters and laboratories in Issy-les- Moulineaux, a suburb of Paris, and its U.S. subsidiary in Rockville, Maryland. For more information, please contact Andrew Lloyd, Andrew Lloyd & Associates: (allo@ala.com), Gilles Petitot (gilles@ala.com) at +33 1 5654 0700 or visit http://www.cytheris.com.


'/>"/>
SOURCE Laureate Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Hurricane Katrina Doctor and Nobel Laureate Headline ASCP Annual Meeting
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology: